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Abstract
Purpose To investigate the mechanistic basis of the anti-
tumor effect of the compound ITB-301.
Methods Chemical modiﬁcations of genistein have been
introduced to improve its solubility and efﬁcacy. The anti-
tumor effects were tested in ovarian cancer cells using
proliferation assays, cell cycle analysis, immunoﬂuores-
cence, and microscopy.
Results In this work, we show that a unique glycoside of
genistein, ITB-301, inhibits the proliferation of SKOv3
ovarian cancer cells. We found that the 50% growth
inhibitory concentration of ITB-301 in SKOv3 cells was
0.5 lM. Similar results were obtained in breast cancer,
ovarian cancer, and acute myelogenous leukemia cell
lines. ITB-301 induced signiﬁcant time- and dose-depen-
dent microtubule depolymerization. This depolymeriza-
tion resulted in mitotic arrest and inhibited proliferation in
all ovarian cancer cell lines examined including SKOv3,
ES2, HeyA8, and HeyA8-MDR cells. The cytotoxic effect
of ITB-301 was dependent on its induction of mitotic
arrest as siRNA-mediated depletion of BUBR1 signiﬁ-
cantly reduced the cytotoxic effects of ITB-301, even at
a concentration of 10 lM. Importantly, efﬂux-mediated
drug resistance did not alter the cytotoxic effect of ITB-
301 in two independent cancer cell models of drug
resistance.
Conclusion These results identify ITB-301 as a novel
anti-tubulin agent that could be used in cancers that are
multidrug resistant. We propose a structural model for the
binding of ITB-301 to a- and b-tubulin dimers on the basis
of molecular docking simulations. This model provides a
rationale for future work aimed at designing of more potent
analogs.
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Introduction
Drugs that effectively interfere with tubulin dynamics pre-
vent mitosis in cancer cells, leading to cell cycle arrest and,
eventually, apoptosis. These drugs are generally classiﬁed
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taxanes and epothilones that induce a net polymerizing
effect and (2) microtubule depolymerizers, such as the
vinca alkaloids colchicine and nocodazole that induce a net
depolymerizing effect [1]. Both types of tubulin inhibitors
have been highly effective in the treatment of a variety of
tumors [2, 3]. However, cancer cells can acquire resistance
to these drugs through multiple mechanisms, including
alterations in microtubule dynamics [4], overexpression of
multidrug-resistance genes [5], delay of the G2/M transition
[6], defects in mitotic checkpoints [7], and alterations in
apoptotic pathways [8]. Thus, the development of novel
anti-tubulin drugs that can escape these acquired resistance
mechanisms is clinically important. ITB-301 (also called
G21) is a novel lipophilic glycoside derivative of genistein
that has been shown to possess potent anti-proliferative
activity in cancer cells through undetermined mechanisms
[9]. In this work, we show that ITB-301 [10] induces severe
microtubule depolymerization and inhibits cancer-cell
proliferation. Importantly, efﬂux-mediated drug resistance
did not affect the efﬁcacy of ITB-301, indicating that ITB-
301 is potentially useful in treating multidrug-resistant
tumors.
Materials and methods
Materials
Compound ITB-301 (Fig. 1a) was a gift from IntertechBio
Corporation and was synthesized using a previously
reported method [9].
Cell lines
All cell lines, excluding the SKOv3-TR cell line, were
obtained from the American Tissue Type Culture Collec-
tion. The SKOv3-TR cell line was obtained from Cell
Services (Cancer Research UK London Research Institute).
Cells were maintained in RPMI-140 medium supplemented
with 10% fetal bovine serum and incubated at 37C and 5%
CO2. The SKOv3-TR cells were maintained in RPMI
supplemented with 0.3 lM paclitaxel.
Proliferation and apoptosis assays
To measure cell proliferation by crystal violet staining,
cancer cells were plated at 5,000 cells per well in 96-well
Fig. 1 The lipophilic disaccharide moiety of genistein signiﬁcantly
increases its cytotoxicity. a The structures of genistein and its
glycoside derivative, ITB-301. b SKOv3 and ES2 ovarian cancer cells
were cultured in 96-well plates (5,000 cells per well) and allowed to
adhere overnight. The cells were then treated with the drugs indicated
at nine different concentrations for 48 h before being ﬁxed and
stained. The percent proliferation compared with untreated cells after
48 h of drug treatment was calculated. Shown is the mean percent
proliferation (±SEM) at each drug concentration calculated from at
least six replicates per concentration
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123plates and allowed to adhere overnight. Cells were treated
with ITB-301, paclitaxel (Sigma–Aldrich), or nocodazole
(Sigma–Aldrich) at the concentrations indicated for 48 h.
Verapamil (Sigma–Aldrich) was used at 10 lM in some
experiments. For the estimation of the number of cells
being treated at the time of drug application (time 0; T0),
replicate plates were used in which cells were ﬁxed rather
than drug-treated. The cells were ﬁxed using 1% glutaral-
dehyde and stained using 0.5% crystal violet in 20%
methanol for 1 h before being thoroughly washed with
water. The dye was solubilized using 100 ll of Sorenson’s
buffer (0.9% sodium citrate, 0.02 N HCl, and 45% etha-
nol), and light absorbance was measured at 540 nm. To
quantify the viability of HL60 cells, the Cell Titer Blue
Assay (Promega) was used according to the manufacturer’s
instructions. In brief, an equal volume of reagent was
added to that of culture medium in each well and incubated
for 3 h at 37C and 5% CO2 followed by measurement of
ﬂuorescence signal from each well using a microtiter plate
reader.
To detect apoptosis, cells (1,500 cells per well) were
incubated in black 384-well plates (Corning), and caspase
3/7 activity was estimated using the Caspase-Glo 3/7 Assay
Reagent (Promega) following the manufacturer’s instruc-
tions. In brief, an equal volume of reagent was added to
that of culture medium in each well and incubated for 1 h
at room temperature followed by measurement of the
luminescence signal from each well using a microtiter plate
reader.
Immunoﬂuorescence and automated microscopy
Subconﬂuent cells growing on cover slips were ﬁxed using
4% paraformaldehyde (PFA) in phosphate-buffered saline
(PBS) for 3–5 min. The cells were washed to remove the
PFA and were incubated in absolute ethanol at -20C for
at least 1 h before being washed with tris-buffered saline,
0.04% SDS (Sigma), and 0.2% Triton X-100 (Sigma–
Aldrich). Blocking was performed using 1.5% bovine
serum albumin in tris-buffered saline. Mouse anti-a-tubulin
antibody (Sigma–Aldrich) was incubated at a 1:100 dilu-
tion in blocking solution for 1 h at room temperature.
The primary antibody was detected using Alexa-488- or
Alexa-594-conjugated anti-mouse antibodies (Invitrogen).
Nuclear DNA was stained using Hoechst 33258 dye
(Invitrogen). Images were observed using an Olympus
FV1000 microscope.
For automated microscopy, the same staining steps were
performed in black 384-well plates (Corning). Eight ima-
ges were collected per well using the In Cell Analyzer 1000
(GE Healthcare) with a Nikon 209 PlanFluo lens (Nikon),
numerical aperture of 0.45, refractive index of 1 and a focal
length of 10,000 pixel width and height; 0.323 and a linear
type of 7 lm. A binning value of 1 9 1 and a gain value
of 2 were used to generate the images (1,392 9 1,040).
The images were analyzed with an In Cell Investigator
software (GE Healthcare) using a multi-target analysis
protocol. For detecting ﬂuorescence signals, the excitation
wavelength of 360 nm and emission of 535 nM were used
for Hoechst stain with an exposure time of 200 ms and
an adjustable offset value, typically at -9.2 lm, and
480/535 nm for Alexa-488 with a typical exposure time of
600 ms and an offset of -0.8 lm. A multi-target analysis
protocol was used for segmentation. Microtubule pixel
intensity was extracted using a top-hat segmentation
method specifying a minimum cell area of 100 lm
2 and
sensitivity for detecting pixel clusters of 74%. In all
high-content experiments, microtubule segmentation was
reviewed in at least 30 randomly selected ﬁelds to check
for appropriate segmentation.
Tubulin in vitro polymerization assay
Measuring in vitro polymerization of tubulin was per-
formed by monitoring turbidity changes in tubulin spec-
trophotometrically at A340 over 60 min using the tubulin
polymerization assay kit (Cytoskeleton) according to
manufacturer’s instructions. In brief, 100 ll volume of
3 mg/ml tubulin in 80 mM PIPES pH 7.0, 0.5 mM EGTA,
2 mM MgCl2, 1 mM GTP, and 10% glycerol was treated
with either DMSO (0.5%), ITB-301 10 lM, paclitaxel
10 lM or Nocodazole 10 lM in 96-well plates. Polymer-
ization was started by incubation at 37C and followed by
absorption readings at 340 nm using the Fusion universal
microplate analyzer (Perkin Elmer). All treatments were
performed in triplicate. To estimate the predicted maxi-
mum tubulin polymer mass, a non-linear curve was ﬁtted
to the time-series data using Michaelis–Menten model
(Graphpad prism 5 software, GraphPad Software, Inc).
Using this method, a goodness of ﬁt R
2 of 0.88 was
obtained for ﬁtting the data from DMSO-treated and ITB-
301-treated tubulin. The alternative hypothesis that the
Vmax was different for each data set was tested at alpha
level of 0.05.
Statistical analysis
The 50% growth inhibitory concentration (GI 50) was
estimated using the following formula: 100 9 (T - T0)/
(C - T0) = 50, where T is the optical density (OD) value
after drug treatment, T0 is the OD value at time 0, and C is
the OD value for the control treatment [11]. Time 0 was
deﬁned as the day the drug was administered. Following
normalization of the OD values for each drug concentration
using the formula described above, the data were ﬁtted
to a non-linear curve using Graphpad Prism 5 software
Cancer Chemother Pharmacol (2011) 68:1033–1044 1035
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tration at which cell proliferation was inhibited by 50%.
Statistical analysis for automated microscopy was con-
ducted using the R environment [12], and graphs were
plotted using the Graphpad Prism software.
Flow cytometry
Cells were treated with the drugs indicated for 24 h and
then trypsinized and ﬁxed with 4% paraformaldehyde for
3 min followed by 70% ethanol at -20C for at least 1 h.
Cells were stained using propidium iodide (Sigma–
Aldrich), processed using an LSR II ﬂow cytometer (BD
Bioscience), and analyzed using the FACSDiva software
(BD Bioscience) to obtain a cell cycle proﬁle. To estimate
the mitotic index, the cells were ﬁxed as described above
for the cell cycle analysis and incubated with an
anti-phospho-histone H3 antibody (Cell Signaling Tech-
nologies). The primary antibody was detected using an
Alexa-488-tagged secondary antibody.
BUBR1 knockdown
Transient knockdown of BUBR1 was performed by trans-
fecting SKOv3 cells with two different siRNA duplexes
targeting BUBR1 or siControl non-targeting siRNA 5
(siGenome library, Dharmacon) using the Dharmafect 4
reagent (Dharmacon) according to the manufacturer’s
instructions and as previously described [4]. In summary,
0.2 llo f2 0lM siRNA was mixed with 0.2 ll of Dhar-
mafect 4 and 20 ll of Optimem medium (Invitrogen) for
20 min in a well of 384-well plate and overlaid with 80 ll
of cell suspension (1,750 cells) in antibiotic-free cell line-
speciﬁc media. This gave a ﬁnal siRNA concentration of
40 nM per well. The sequences for the siRNAs used were
as follows; BUBR1 siRNA 1, 50-GGAAGAAGAUCUAGA
UGUA-30 and BUBR1 siRNA 2, 50-CAAGAUGGCUGU
AUUGUUU-30.
Docking of ITB-301 to microtubules
Since microtubules are assembled from a- and b-tubulin
dimers, in our studies, the structure of a model dimer was
taken from the crystallographic data of a- and b-tubulin
stabilized by paclitaxel [13], PDB code—1JFF. A model
tubulin dimer complexed with colchicine was built using
the crystallographic structure of b-tubulin complexed with
colchicine [14], PDB code—ISA0, by replacing b-tubulin
complexed with paclitaxel. The locations of colchicine and
paclitaxel in their binding pockets are hereafter referred to
as ‘‘the colchicine binding site’’ and ‘‘the paclitaxel binding
site,’’ respectively. The MOE molecular modeling library
[15] was used in the modeling studies. The reference
structures were assigned hydrogen atoms using routine
procedures implemented in MOE. Both structures were
optimized by the energy minimization. Next, colchicine
and paclitaxel were removed. Genistein was docked into
the colchicine binding site, and ITB-301 was docked into
the colchicine and paclitaxel binding sites using MOE
docking technologies. Initial conﬁgurations were created
manually using a 3D visualization system and by careful
analysis of possible binding modes. In particular, selected
positions of ITB-301 with its genistein fragment inside and
outside the colchicine and paclitaxel binding sites were
probed. The resulting possible binding modes were scored
and relaxed by the energy minimization. Because ITB-301
is relatively large and its locations in the binding sites can
be affected by interactions with the environment, the
structural stability of the 16 most probable ITB-301-tubulin
complexes in a water solution was tested by carrying out
1-ns molecular dynamics simulations, which were pre-
ceded by careful thermalization and equilibration of the
systems. The above-mentioned simulations were carried
out for the two model systems at T = 310 K, atmospheric
pressure, and an ionic strength of 0.05 M in a rectangular
cuboid. The ﬁrst system consisted of a- and b-tubulin
complexed with ITB-301 in the colchicine binding site and
surrounded by 32,255 water molecules. The second system
consisted of an a-b-a-tubulin trimer complexed with ITB-
301 in the paclitaxel binding site and surrounded by 23,844
water molecules. This allowed for the drug to be located
approximately in the center of the simulated system. The
NAMD library [16, 17] capable of carrying out simulations
for large molecular systems with scalable parallel MD
algorithms was used. The CHARMM27 force ﬁeld [18] and
a TIP3P water model [19] were applied.
Results
ITB-301 inhibits cell proliferation and induces cell
cycle arrest in ovarian cancer cells
In contrast to genistein, ITB-301 signiﬁcantly inhibited the
proliferation of SKOv3 ovarian cancer cells over the range
of concentrations tested (0–10 lM, Fig. 1b). The GI50 of
ITB-301 in SKOv3 cells was 0.52 lM (Fig. 2). Similar
results were obtained for the ovarian cancer cell line ES2
and the breast cancer cell line HCC194 (Fig. 2). To
investigate the cause of the cell-proliferation arrest fol-
lowing ITB-301 administration, we examined the cell cycle
progression of SKOv3 cells, both before and after ITB-301
treatment, using ﬂow cytometry. We found that 93% of the
cells were arrested in the G2/M phase of the cell cycle 24 h
after treatment, and 63% of these cells were arrested in
mitosis, as evidenced by positive anti-phospho-histone H3
1036 Cancer Chemother Pharmacol (2011) 68:1033–1044
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arrest of cells in mitosis by ITB-301 treatment is similar to
the effect obtained when cells are treated with the anti-
tubulin drugs paclitaxel and nocodazole (Fig. 3). Similar
results were obtained in ES2, paclitaxel-sensitive HeyA8
and HeyA8 paclitaxel-resistant ovarian cancer cell lines
(Supplementary Fig. 1).
ITB-301 induces microtubule depolymerization
Because ITB-301 induced mitotic arrest similar to anti-
tubulin agents, we hypothesized that ITB-301 treatment
resulted in microtubule damage. To quantify the effect of
ITB-301 on microtubules, we treated SKOv3 cells with
10 lM ITB-301 for 24 h and then examined the microtu-
bule mass using automated microscopy and image analysis.
The microtubule mass decreased signiﬁcantly (P\0.0001,
t test) following ITB-301 treatment, and this was similar to
the decrease in mass produced by treatment with 2 lM
nocodazole. In contrast, treatment with 100 nM paclitaxel
produced a signiﬁcant increase in the microtubule mass
(Fig. 4a, c–f). Treatment with ITB-301 induced a dose- and
time-dependent decrease in the microtubule mass (Fig. 4b).
Confocal microscopy was then used to qualitatively assess
the effect of ITB-301 treatment on microtubules. Treat-
ment of cells with ITB-301 at the GI50 concentration
(0.5 lM) induced loss of microtubule structure within 1 h,
in a manner similar to that achieved by treatment with
nocodazole at the GI50 concentration (Fig. 4h and i). In
contrast, paclitaxel induced the formation of characteristic
microtubule bundles (Fig. 4g and j). Importantly, ITB-301
also induced microtubule depolymerization in ES2, pac-
litaxel-sensitive HeyA8, and HeyA8 paclitaxel-resistant
ovarian cancer cell lines (Supplementary Fig. 1).
To test whether ITB-301 directly interacted with tubu-
lin, in vitro polymerization assays were performed. Tubulin
polymerization was determined in vitro by monitoring
turbidity changes in tubulin spectrophotometrically at A340
Fig. 2 ITB-301 induces signiﬁcant cytotoxicity in ovarian (ES2) and
breast cancer (HCC194) cell lines. Cancer cells were cultured in
96-well plates (5,000 cells per well) and allowed to adhere overnight.
Cells were then treated with the indicated drugs at nine different
concentrations for 48 h before being ﬁxed and stained. The percent
proliferation compared with untreated cells after 48 h of drug
treatment was calculated. Shown is the mean percent proliferation
(±SEM) calculated from at least six replicates per concentration from
two independent experiments
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tubule mass. As expected, this showed that paclitaxel sig-
niﬁcantly enhanced microtubule polymerization (Fig. 4k).
In contrast, nocodazole and ITB-301 decreased tubulin
polymerization over time (Fig. 4k). To calculate the max-
imum predicted tubulin polymer mass (Vmax) over time, a
non-linear curve was ﬁtted to the time-series data
(Michaelis–menten equation, Graphpad Prism). This anal-
ysis revealed that ITB-301 at 10 lM concentration signif-
icantly decreased the maximum predicted tubulin polymer
mass over time by 12% compared with DMSO-treatment
(predicted OD value of 0.22 and 0.25, respectively,
P\0.0001).
BUBR1 is required for ITB-301-induced cytotoxicity
Microtubule-targeting agents induce sustained activation of
mitotic checkpoint regulators, such as BUBR1 and MAD2,
resulting in apoptosis and cell death [20]. We hypothesized
that ITB-301 induces microtubule depolymerization that
results in mitotic checkpoint-dependent apoptosis and cell
death. We ﬁrst showed that ITB-301 induced apoptosis in
SKOv3 cells in a dose-dependent manner (Fig. 5a). To test
whether the ITB-301-induced apoptosis was dependent on
intact mitotic checkpoints, we depleted BUBR1 in SKOV3
cells using two independent BUBR1-targeting siRNAs
before treating cells with ITB-301. BUBR1 depletion
Fig. 3 ITB-301 induces mitotic
arrest in SKOv3 cells. SKOv3
cells were treated with different
drugs for 24 h before the cells
were ﬁxed and stained for cell
cycle analysis using propidium
iodide staining or the
determination of the mitotic
index using anti-phospho-
histone H3 staining tagged with
Alexa-488. Shown are typical
results from two independent
experiments
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at all three concentrations tested (P\0.001, one-way
ANOVA; Fig. 5b). Similar results were obtained using
cell-proliferation assays (Fig. 5c). From these results, we
concluded that the ITB-301-mediated cytotoxicity was
dependent on active mitotic checkpoints.
Fig. 4 ITB-301 induces signiﬁcant microtubule depolymerization.
a and b SKOv3 cells were treated with drugs and then ﬁxed and
stained as described in the ‘‘Materials and methods’’. Shown is the
mean of the background (BG)-corrected intensity values (±SEM)
for a-tubulin staining from at least 500 cells from triplicate wells.
c–f Representative images from which the data in panel a were
derived are shown. g–j Projected images of confocal microscopy
Z-stacks of SKOv3 cells treated with the drugs indicated for 1 h
before being ﬁxed and stained using an a-tubulin antibody. Note the
loss of microtubule architecture in panels h and i and the microtubule
bundles in panel j (arrowhead). k 100 ll volume of 3 mg/ml tubulin
was incubated with either 0.5% DMSO (control), 10 lM ITB-301,
10 lM paclitaxel, or 10 lM Nocodazole in 96-well plates in
triplicates. Tubulin polymerization was started by incubation at
37C and followed over 60 min by absorption readings at 340 nm.
Scale bar = 5 lm
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Drug efﬂux has been shown to be a signiﬁcant cause of
clinical resistance to multiple drugs [21]. We asked whe-
ther this mode of drug resistance might also result in
resistance to ITB-301. To test this possibility, we used an
established model of efﬂux-mediated chemotherapy resis-
tance: the parent acute myelogenous leukemia cell line
HL60 and the daughter doxorubicin-resistant cell line
HL60-dox. HL60-dox overexpresses the multidrug-resis-
tant protein (MRP) [22, 23], whereas the parent line does
not. As expected, the HL60-dox cells were highly resistant
to paclitaxel. The minimum effective dose of paclitaxel
that was required to signiﬁcantly inhibit HL60-dox prolif-
eration was at least 400-fold greater than that required to
inhibit HL60 proliferation (from 12.5 nM for HL60
to 5 lM for HL60-dox; Fig. 6a). In contrast, there was no
change in the minimum effective dose of ITB-301 (5 lM
for both cell lines; Fig. 6b). This result indicated that the
effectiveness of ITB-301 was not affected by the presence
of the MRP gene product. Similar results were obtained in
the ovarian cancer–sensitive HeyA8 cells and the derived
paclitaxel-resistant HeyA8-MDR that is known to overex-
press the MDR gene (Supplementary Fig 2). To further
conﬁrm this ﬁnding, we used a third model of resistance
that is based on drug efﬂux: the parent paclitaxel-sensitive
ovarian cancer cell line SKOv3 and the daughter paclit-
axel-resistant cell line SKOV3-TR, which is known to
overexpress MDR1 [4, 24]. The minimum effective dose of
paclitaxel for the SKOV3-TR cells was at least 100-fold
greater than that for the parent SKOV3 cells (1 lM and
10 nM, respectively; Fig. 6c). Co-treatment of cells with
paclitaxel and verapamil, an MDR1 resistance-reversing
agent, resensitized the SKOv3-TR cells to the 10-nM
paclitaxel treatment. In contrast, the minimum effective
dose (10 lM) of ITB-301 that signiﬁcantly inhibited pro-
liferation of SKOv3-TR cells (tenfold higher than the dose
required for the parent SKOv3 cells) was not affected by
the presence of verapamil (Fig. 6d). This result provided
further conﬁrmation that the efﬁcacy of ITB-301 is not
altered by drug-efﬂux resistance mechanisms.
Theoretical modeling of ITB-301 binding to tubulin
supports a depolymerizing mechanism of action
We next sought to compare the theoretical microtubule
binding of ITB-301 to the binding of the known anti-
tubulin drugs colchicine and paclitaxel. Packing ITB-301
in the tight paclitaxel binding site may result in local, steric
hindrances and is, therefore, less likely to occur. A more
plausible site that would accommodate the size and struc-
ture of ITB-301 may be between the a- and b-tubulin
Fig. 5 BUBR1 is required for ITB-301-induced cytotoxicity.
a SKOv3 cells were plated in a 384-well plate (2,000 cells per well)
and permitted to adhere overnight. Cells were treated with ITB-301 at
the concentrations shown for 48 h, and caspase 3/7 activity was
determined. b SKOV3 cells were transfected using either two
independent siRNAs targeting BUBR1 or non-targeting control
siRNAs. Cells were treated with ITB-301 at the concentrations
shown for 48 h, and caspase 3/7 activity was determined. The data
shown in panels a and b represent the fold-change (±SD) in caspase
3/7 activity between the ITB-301-treated cells and the vehicle-treated
controls. All values were measured in triplicate. c The cells were
treated with siRNA as described in panel b, and the cell proliferation
was estimated using crystal violet staining. Data shown are the mean
percent cell proliferation at each drug concentration (±SD) normal-
ized to vehicle-treated controls. All values were measured in triplicate
1040 Cancer Chemother Pharmacol (2011) 68:1033–1044
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izing agent binds at this site (Fig. 7a). Docking studies with
MOE in implicit solvent have shown that (1) potential
complexes of ITB-301 in the colchicine binding site were
more probable than potential complexes of ITB-301 in the
paclitaxel binding site and (2) positions of ITB-301
whereby its genistein fragment resides inside the binding
pockets were typically more probable than those with the
genistein fragment outside the binding pockets (Fig. 7b).
These ﬁndings were reﬁned by 1-ns molecular dynamics
simulation runs in the explicit water solution starting from
the 16 most probable cases selected from the docking
studies. In each case, the mean interaction energies
between ITB-301 and protein environments (including
water molecules) in a sphere of 7 A ˚ were computed. The
residue-based cutoff criterion was applied. Complexes of
ITB-301 in the colchicine binding site appeared to be more
stable than those with ITB-301 in the paclitaxel binding
Fig. 6 Multidrug resistance does not signiﬁcantly alter the cytotoxic
effect of ITB-301. a and b The parental HL60 acute myelogenous
leukemia cells and the HL60-derived MRP1-overexpressing cells
(HL60-dox) were plated in a 384-well plate (2,000 cells per well) and
treated with the drugs at the indicated concentrations for 48 h, and the
cell viability was estimated as described in methods. Data shown are
the mean percent cell viability at each drug concentration (±SD)
normalized to vehicle-treated controls. All values were measured in
triplicate. c and d The parental SKOv3 paclitaxel-sensitive cells and
the SKOv3-derived paclitaxel-resistant cells (SKOv3-TR) were plated
in 96-well plates and allowed to adhere overnight. The cells were
treated with the indicated concentrations of either paclitaxel or ITB-
301, with or without verapamil (10 lM) as indicated, for 72 h. The
cells were ﬁxed and stained using crystal violet. Data shown represent
the mean percent cell growth at each drug concentration (±SD)
normalized to vehicle-treated control cells. All values were measured
in triplicate
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of ITB-301 with tubulin in the colchicine and the paclitaxel
binding sites were selected. Their structures are depicted in
Fig. 7c, d, respectively. The energy difference results
mainly from unpreferable local interactions of ITB-301 in
the paclitaxel binding site. These theoretical ﬁndings are in
line with our experimental data, suggesting that intermo-
lecular interactions of ITB-301 are more similar to that of
colchicine than paclitaxel.
Discussion
Genistein is one of the most intensively studied naturally
occurring ﬂavonoids and is commonly present in soy-
derived products. It is generally accepted that genistein
demonstrates considerable anticancer potential, with mul-
tiple mechanisms of action [25–27]. However, genistein’s
low solubility in both aqueous and lipid environments
limits its potential to be developed as a drug. Attempts to
alter its bioavailability using derivatization with water-
soluble molecules included the synthesis of sugar glyco-
sides of genistein. Conjugation of genistein with a sugar
derived from peracetylated lactose resulted in a compound,
ITB-301, that was signiﬁcantly more potent than other
glycosides [9]. Surprisingly for a genistein derivative, our
studies demonstrated for the ﬁrst time that ITB-301 can
induce signiﬁcant dose- and time-dependent microtubule
depolymerization [10]. A recent study provided further,
although only qualitative, evidence of the effect of ITB-
301 on microtubules [28]. In summary, our detailed studies
of the mechanism of action of ITB-301 provided evidence
that the cytotoxic effect of ITB-301 is almost exclusively
the result of induction of microtubule depolymerization
and subsequent mitotic arrest.
The precise mechanism of apoptosis induction following
anti-tubulin drug treatment is unknown. However, there is
strong evidence that intact mitotic checkpoints are crucial
for the induction of mitotic arrest and apoptosis following
anti-tubulin drug treatment [7, 20]. In this work, we found
that depletion of BUBR1 nearly abolished the apoptosis
induced by ITB-301. This ﬁnding conﬁrms that, similar to
anti-tubulin drugs, the cytotoxicity of ITB-301 requires
intact mitotic checkpoints and is dependent on microtubule
depolymerization.
How genistein and ITB-301 bind to tubulin and why
ITB-301 induces depolymerization rather than stabilization
remain to be identiﬁed. It is interesting to note that the
genistein part of ITB-301 is capable of binding in the col-
chicine binding pocket at the interface between the
a- and b-tubulin molecules. Binding of colchicine at this
site requires a twist in the tubulin dimer conformation, and
Fig. 7 A structural model for binding of genistein and ITB-301 to
tubulin dimers. a Structural models for binding of colchicine and
paclitaxel to tubulin dimers are shown: a-tubulin (blue), b-tubulin
(red), GTP (yellow), GDP (light blue), colchicine (green), and
paclitaxel (white). b The three most probable positions of genistein in
the colchicine binding site; the position shown in white has the largest
overlap with the colchicine crystallographic location. GTP is colored
yellow and the magnesium ion shown as an orange sphere. c The most
stable position of ITB-301 (green) in the colchicine binding site. Note
that the genistein fragment of ITB-301 penetrates the colchicine
binding site, while the lipophilic disaccharide tail is located in the
interface region between a- and b-tubulin. d Possible position of ITB-
301 (green) in the paclitaxel binding site
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123this prevents the necessary straight conformation that is
needed for microtubule assembly [29]. While genistein
alone seems to be capable of such binding, it is either
incapable of or inefﬁcient in inducing microtubule depo-
lymerization. The lipophilic disaccharide tail of ITB-301
seems to be the key structural element allowing for effec-
tive microtubule depolymerization. Its location in the
interface region between the a- and b-tubulin may either
result in their separation or prevent the addition of new b-
tubulin molecules at the microtubule end. This plausible
model allows for a more rational design of novel deriva-
tives of genistein with potent microtubule-depolymerizing
properties and extends our knowledge of the mechanisms
of tubulin drug binding and tubulin polymerization/depo-
lymerization processes.
Acquired drug resistance via overexpression of trans-
membrane protein pumps that actively export drugs outside
the cell is thought to be an important cause of clinical che-
motherapy resistance [5, 23, 30]. Finding novel drugs with
therapeutic effects similar to those of established chemo-
therapeutic agents but that are unaffected by drug-efﬂux
pumps is highly desirable. Here, we showed that ITB-301
induced similar cytotoxic effects in both drug-sensitive
leukemia cells and drug-resistant leukemia cells that over-
express MRP1 (HLA60-dox cells). In SKOv3-TR cells, we
showed that the inhibition of MDR1 did not increase the
cytotoxic effect of ITB-301, conﬁrming that ITB-301 is not
asubstrateforMDR1-inducedexocytosis.Wespeculatethat
the observed increase in ITB-301 resistance in SKOv3-TR
may relate to other acquired resistance mechanisms. Our
results indicate that ITB-301 could be used to treat cancers
that have developed multidrug resistance. Interestingly,
dimers of natural ﬂavonoids, the same family to which
genistein belongs, have recently been shown to inhibit
MDR1-mediated drug efﬂux [31]. These dimers have been
shown to reduce the IC50 of microtubule-targeting agents
by up to 50-fold in models of drug resistance in vitro [31].
In summary, this work demonstrates that ITB-301
exhibits tubulin-depolymerizing characteristics against
both drug-sensitive and multidrug-resistant cancer cell
lines. Theoretical modeling of the mode of binding of ITB-
301 to tubulin provides a rationale for the design of even
more potent analogs.
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